Zobrazeno 31 - 40
of 43
pro vyhledávání: '"Toyoaki Hida"'
Autor:
Junichi Shimizu, Toyoaki Hida, K. Tanaka, Yoshitsugu Horio, Y. Yatabe, Yuko Oya, Teruhiko Yoshida
Publikováno v:
Annals of Oncology. 26:ix125
Autor:
Yuko Oya, Toyoaki Hida, Y. Yatabe, H. Yoshitsugu, S. Junichi, Tatsuya Yoshida, Kiyoshi Tanaka
Publikováno v:
European Journal of Cancer. 51:S619
Autor:
Kimihide Yoshida, Chiaki Kondo, Susumu Hijioka, Yoshitsugu Horio, Jangchul Park, Junichi Shimizu, Toyoaki Hida
Publikováno v:
Lung Cancer. 81:495-496
This report describes esophageal ulcer as a novel adverse event associated with crizotinib therapy. Although crizotinib is generally well tolerated, physicians should be aware of the possibility of this adverse event.
Autor:
Yoshitsugu Horio, Kosuke Tanaka, Junichi Shimizu, Yuko Oya, Yasushi Yatabe, Tatsuya Yoshida, Toyoaki Hida
Publikováno v:
Journal of Clinical Oncology. 33:e19138-e19138
e19138 Background: The next generation ALK inhibitor, alectinib, reportedly has potent efficacy after crizotinib failure in ALK-positive NSCLC patients. In the present study, we investigated progre...
Autor:
Filippo deMarinis, Massimiliano Quadrigli, Giorgio V. Scagliotti, David R. Spigel, Enriqueta Felip, Jie Zhang, Chetachi Emeremni, Harry J.M. Groen, Fabrice Branle, Heather A. Wakelee, Makoto Nishio, Alice T. Shaw, Toyoaki Hida, Lucio Crinò, Myung-Ju Ahn, Tony Mok
Publikováno v:
Journal of Clinical Oncology. 33:8059-8059
8059 Background: In the ASCEND-1 study ceritinib showed clinical activity in pts with ALK+ NSCLC, including in brain metastases (BM). ASCEND-2 (NCT01685060) evaluated efficacy and safety of ceritin...
Autor:
Kentaro Takeda, Tomohiro Tanaka, M. Nishio, Haruyasu Murakami, Yuichiro Ohe, Toyoaki Hida, Miyako Satouchi, Kazuhiko Nakagawa, Takashi Seto, Masahiro Tatsuno, Katsuyuki Hotta, Tomohide Tamura, Tadashi Shimada
Publikováno v:
Annals of Oncology. 25:iv427
Aim: Alectinib is a CNS-penentrant, highly selective ALK inhibitor with a novel scaffold. JP28927 is a clinical pharmacological study to evaluate the bioequivalence of alectinib 300 mg b.i.d. with 20 and 40 mg capsules (caps) vs. 150 mg caps and food
Autor:
Junichi Shimizu, Y. Yatabe, Toyoaki Hida, C. Kondo, Kimihide Yoshida, Yoshitsugu Horio, Ji Young Park, Tetsuya Mitsudomi
Publikováno v:
Annals of Oncology. 23:ix433-ix434
Background The purpose of this study is to investigate the clinical characteristics and the efficacy of the cytotoxic chemotherapy in the first and second line setting in EML4-ALK positive NSCLC with advanced stage. Methods EML4-ALK fusion was screen
Autor:
Kazuhiko Nakagawa, Koji Takeda, Toyoaki Hida, Masahiro Tatsuno, Naoki Yoshikawa, Yuichiro Ohe, Tomohiro Tanaka, Haruyasu Murakami, Makoto Nishio, Tomohide Tamura, Takashi Seto, Miyako Satouchi, Katsuyuki Hotta
Publikováno v:
Journal of Clinical Oncology. 32:8103-8103
8103 Background: Alectinib, a potent highly selective ALK inhibitor, shows good efficacy and safety for crizotinib-naive and -resistant patients (pts) with ALK-rearranged non-small cell lung cancer (NSCLC). However, each dose required 8 capsules (cap
Autor:
Editta Baldini, N. Yamamoto, Miyako Satouchi, G. J. Riely, Anna Polli, S. Salvatore, Toyoaki Hida, Leora Horn, Hiroshi Nokihara, J-Y. Han
Publikováno v:
Annals of Oncology. 24:ix43
Autor:
Ji-Youn Han, Benjamin Solomon, Miyako Satouchi, V. Tassell, Nobuyuki Yamamoto, Editta Baldini, Shirish M. Gadgeel, Hiroshi Nokihara, Salvatore Siena, Toyoaki Hida, Anna Polli, D. Ross Camidge, Gregory J. Riely, Leora Horn, Scott N. Gettinger
Publikováno v:
Journal of Clinical Oncology. 31:8105-8105
8105 Background: PROFILE 1007 compared the efficacy and safety of crizotinib with that of standard-of-care chemotherapy in patients with ALK+ NSCLC. Although the study was not designed for formal assessment of patient outcomes on crizotinib vs. PEM o